In last trading session, Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) saw 1.76 million shares changing hands with its beta currently measuring 0.50. Company’s recent per share price level of $2.49 trading at -$0.16 or -6.04% at ring of the bell on the day assigns it a market valuation of $3.29M. That closing price of CYCC’s stock is at a discount of -430.12% from its 52-week high price of $13.20 and is indicating a premium of 47.79% from its 52-week low price of $1.30. Taking a look at company’s average trading volume volume of 756.69K if we extend that period to 3-months.

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information

Upright in the red during last session for losing -6.04%, in the last five days CYCC remained trading in the green while hitting it’s week-highest on Wednesday, 05/01/24 when the stock touched $2.49 price level, adding 37.75% to its value on the day. Cyclacel Pharmaceuticals Inc’s shares saw a change of -6.74% in year-to-date performance and have moved 55.62% in past 5-day. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) showed a performance of 13.70% in past 30-days.

Cyclacel Pharmaceuticals Inc (CYCC) estimates and forecasts

Statistics highlight that Cyclacel Pharmaceuticals Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -69.18% of value to its shares in past 6 months, showing an annual growth rate of 30.09% while that of industry is 12.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 32.13% during past 5 years.

CYCC Dividends

Cyclacel Pharmaceuticals Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.